Disclosure of interest: Nothing to Disclose Scientific Communications: prognosis & outcomes 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE O - ESOC25-76 LONGITUDINAL BRAIN AGEING AFTER STROKE: A MARKER FOR SECONDARY POST-STROKE DEGENERATION AND ITS RELEVANCE FOR MOTOR OUTCOME Raphael Takyi 1 , Jeanette Plantin 2 , Sylvain Charron 1 , Marc Maier 3 , Jean-Claude Baron 4 , Guillaume Turc 5 , Rosso Charlotte 6 , Clment Debacker 1 , Pavel Lindberg 1 1 Institute of Psychiatry and Neuroscience of Paris, Paris, France, 2 Karolinska Institute, Stockholm, Sweden, 3 Universit Paris Cit, INCC UMR 8002, CNRS, Paris, France, 4 Institute of Psychiatry and Neuroscience of Paris, GHU-Paris Psychiatrie et Neurosciences - Neurology, Paris, France, 5 GHU-Paris Psychiatrie et Neuroscience - Neurology, Institute of Psychiatry and Neuroscience of Paris, Paris, France, 6 Sorbonne Universit, Inserm U 1127, APHP Urgences CrebroVasculaires, Hpital Piti- Salptrire, CNRS UMR 7225, STARE team, iCRIN, Inst

Medicare is prohibited from covering weight loss drugs by legislation, but the Center for Medicare and Medicaid Services told Part D plans that they could provide coverage for GLP-1s for those with known heart disease
As GLP-1s help improve mobility and reduce pain tied to conditions like osteoarthritis, they can enable more consumers to re-engage with healthier lifestyles, from exercise to more intentional nutrition
Cardiovascular event rates don't increase